Covid 19 Research using Clinical Trials (Home Page)
Aviptadil (VIP)Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug91 | BCG Wiki | 1.00 |
| drug616 | Placebo Wiki | 0.10 |
Correlated MeSH Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004417 | Dyspnea NIH | 0.58 |
| D014947 | Wounds and Injuries NIH | 0.41 |
| D055370 | Lung Injury NIH | 0.32 |
| D055371 | Acute Lung Injury NIH | 0.16 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.15 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.13 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Acute Respiratory Distress Syndrome and the need for mechanical ventilation. Mortality rates as high as 80% have been reported among those who develop ARDS, despite intensive care and mechanical ventilation. Patients with COVID-19 induced non-Acute Lung Injury who have demonstrated reduction in blood oxygenation, dyspnea, and exercise intolerance but do not require endotracheal intubation and mechanical ventilation will be treated with Aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP) plus Standard of Care vs. placebo + Standard of Care. Patients will be randomized to intravenous Aviptadil will receive inhaled Aviptadil, 100 μg 3x daily vs. placebo 3x daily. The primary outcome will be progression to ARDS over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.
NCT04360096 SARS-CoV 2 COVID ARDS ALI Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) Dyspnea Drug: Aviptadil (VIP) Drug: Placebo MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea Lung Injury Wounds and Injuries
HPO:Dyspnea Respiratory distress
Primary Outcomes
Description: Progression to ARDS is defined as the need for mechanical ventilation
Measure: Progression to ARDS Time: 28 days
Secondary Outcomes
Description: Blood PO2 as measured by pulse oximetry
Measure: Blood oxygenation Time: 28 days
Description: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath
= very mild shortness of breath
= mild shortness of breath
= moderate shortness of breath or breathing difficulty
= somewhat severe shortness of breath
= strong or hard breathing
7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity
Measure: RDP Dsypnea Scale Time: 28 days
Description: Distance walked in six minutes
Measure: Distance walked in six minutes Time: 28 days
Related HPO nodes (Using clinical trials)
HP:0002094: Dyspnea
Genes 452
DNAH9 DOK7 COL13A1 ND5 EPHB4 SBDS TBC1D24 SPAG1 ORC1 ZFPM2 ABCG8 GAS2L2 CHRNB1 DNA2 LYRM4 CHRNE CRELD1 TET2 RAPSN ATRX TERT SQSTM1 PLEC CASR PON2 ENG COLQ DNAAF4 ALDH7A1 MYO9A SCN4A IRF2BP2 OPTN SLC18A3 FGFR2 MYL3 CFAP300 MARS1 RUNX2 DNAI1 TRAK1 SFTPA2 COX6B1 RSPH1 CRLF1 MFAP5 SLC2A10 DNAL1 ND2 ZMYND10 FUS NKX2-1 TTN SURF1 COX8A MMAB CYB5A GBA GAS8 PUF60 PRRT2 IFT52 TBL1XR1 SFTPA1 PNKD NPPA FIP1L1 EP300 COX14 MPC1 COL2A1 BMPER NDUFS2 MUC5B BCOR DNAAF1 PRSS1 PET100 SRP54 FAM20C COX20 EOMES TRMT5 CSPP1 RPS28 NABP1 SCN1B TSC1 AIFM1 TGFB2 DNAAF6 NUMA1 STN1 PRRX1 SFTPC ISCU SLC25A3 LAMB2 SLC5A7 VCP SPEF2 LIFR TGFBR1 SMPD1 LDLRAP1 LGI4 MAT2A COA8 RPS26 SERPING1 LAMB3 ADCY6 FOXE3 SMAD4 EIF2AK4 IL1RN ND4 TRIP11 GBA NGLY1 STAT5B POLG CCR6 GATA6 ANG MUSK C1R MMUT DBH SFTPB MRPL3 HNRNPA1 GATA6 CFAP410 PFN1 SFTPC CSF2RB SDCCAG8 DSC2 ADAMTS13 JAK2 GNAS PRKCSH ZIC3 C9ORF72 FASTKD2 ETFB SPP1 CSF2RB NDUFB8 CHAT STK36 CHCHD10 NPM1 PRKAR1A SCN5A KLHL7 CNTNAP1 RSPH3 CYB5R3 GNAI3 PCSK9 FBLN5 CCN2 DRC1 VAMP1 ADNP CPT2 TREM2 LDLR LRRC56 LRRC6 BTNL2 CCDC40 SLC25A1 STX16 CFTR COQ7 GATA6 HLA-DRB1 FOXF1 EFEMP2 DAO GYG1 PLCB4 UBE3B C1QA SMAD3 TSC2 ITGA3 SCNN1B DSP DNAI2 CFTR SOX9 DNAJC21 SCO1 SYT2 USP9X RRM2B DPM2 FGFR2 SSR4 BTNL2 COX10 CDC6 ERBB4 VCL GLA CCDC114 PON3 ACVRL1 DYNC2LI1 GLE1 ZBTB16 CDC45 NEK1 MGME1 RPGR ATP6 CREBBP CLCNKB CTRC DPM2 BMPER SPINK1 STAT5B ERF HYDIN DNAH11 FBN1 APOB TRNW CHRND COA8 ND6 DNAAF3 CCDC151 PRPH UBQLN2 DISC1 ATP11A SCN4A TRNV STT3B TGFBR2 NDUFAF3 IFT81 WIPF1 GATA4 CDT1 ETFA DNAJB6 TRMU RSPH4A GBA HLA-B TACO1 SLC52A3 DPP9 NME8 COL2A1 FBP1 TERC AGRN TWNK CCDC65 GLT8D1 TRNN STAT4 CYB5R3 PML ORC1 LTBP3 MYH11 SOD1 FLNC RARA LRP4 CCDC39 PMM2 TRNK ORC4 BMPR2 AK9 SFTPC DMPK MAPT MYH11 IRF5 KAT6A NR2F2 SLC35A1 NUP214 CHRND ORC6 TET2 CFAP298 DPM1 FGFR1 ATXN2 TRNE DNAAF2 MATR3 GMNN ORC6 NAGS SCN4A NEFH PIGT HLCS SLC25A4 CCNF PRKG1 ANXA11 MYLK VCP HLA-DRB1 CSF2RA FIG4 TARDBP VAPB AIMP2 HCCS DNASE1L3 ELN STT3B DNAH5 SETBP1 OTX2 RTEL1 SFTPA2 ACADM TTC25 UNC13A LOX DNAAF5 STAT3 CHRNE TRIP11 TBX4 NEB ABCG5 TUBB4A NAGS ACADVL CAV1 TK2 GAA ARMC4 CHRNA1 SNAP25 MUC5B ND3 POLG2 COL2A1 EFTUD2 PON1 TNNC1 ARX KCNA1 FOXP3 CFAP221 DNA2 MAPT KCNJ6 EPHA4 COPA DCTN1 TGFB3 MMAA ABCA3 PARN RNU4ATAC CHMP2B XYLT1 NOD2 VPS33A FOXJ1 MEGF10 PRKAR1A CHAT SLC25A1 CAV1 CCNO SERPINA1 PPARGC1A FGFR2 SCN5A TRPM4 TRNS1 POMT1 TRNE DNAH1 RSPH9 TRNL1 PRRX1 TAF15 EDN1 WAS JPH2 PGM1 COX7B CCDC103 ND1 HLA-DRB1 DNAAF3 IKZF1 LAMA3 SH2B3 SLC12A3 CHRNB1 LAMC2 TBK1 ABCA3 SCO2 TERT EDA ALAS2 SCO2 DMPK MGME1 GNAS NKX2-1 GNAS OFD1 TRNK ACTA2 COL13A1 ETFDH COL2A1 FAM13A IRAK1 MYL2 SCNN1A HBB USP9X SCNN1G NDUFB11 CHRNE FGFR2 TRPV6 DNAJB13 MYBPC3 SIK1 CHRNA1 MMUT EPOR FBP1 NKX2-5 AGRN MCIDAS Protein Mutations 0
SNP 0
HP:0002098: Respiratory distress
Genes 230
DNAH9 DNAH11 ND5 EPHB4 SBDS TBC1D24 SPAG1 ORC1 TRNW ZFPM2 ND6 DNAAF3 GAS2L2 CCDC151 LYRM4 DISC1 CHRNE TRNV STT3B NDUFAF3 IFT81 CDT1 ETFA TRMU RSPH4A GBA TACO1 SLC52A3 NME8 COL2A1 COLQ FBP1 DNAAF4 ALDH7A1 MYO9A AGRN CCDC65 SLC18A3 TRNN FGFR2 ORC1 CFAP300 RUNX2 DNAI1 TRAK1 COX6B1 RSPH1 CCDC39 PMM2 ORC4 SLC2A10 DMPK DNAL1 MAPT ND2 ZMYND10 KAT6A NKX2-1 SURF1 COX8A MMAB SLC35A1 NUP214 GBA GAS8 CFAP298 DPM1 FGFR1 PUF60 IFT52 EP300 TRNE COX14 DNAAF2 MPC1 COL2A1 GMNN BMPER NDUFS2 ORC6 NAGS DNAAF1 PRSS1 PET100 SRP54 HLCS FAM20C COX20 EOMES CSF2RA RPS28 AIMP2 AIFM1 HCCS DNAAF6 STT3B DNAH5 SETBP1 PRRX1 SFTPC OTX2 SLC25A3 TTC25 LAMB2 SLC5A7 SPEF2 DNAAF5 TRIP11 LIFR TUBB4A NAGS ACADVL TK2 LGI4 ARMC4 COA8 SNAP25 ND3 RPS26 SERPING1 COL2A1 EFTUD2 ADCY6 KCNA1 FOXP3 CFAP221 IL1RN ND4 TRIP11 NGLY1 STAT5B MAPT COPA GATA6 MMAA MMUT ABCA3 SFTPB XYLT1 GATA6 VPS33A FOXJ1 CSF2RB MEGF10 SDCCAG8 ADAMTS13 ZIC3 CHAT FASTKD2 ETFB CCNO NDUFB8 CHAT STK36 FGFR2 TRNS1 KLHL7 POMT1 TRNE CNTNAP1 DNAH1 RSPH3 RSPH9 GNAI3 FBLN5 TRNL1 PRRX1 EDN1 DRC1 VAMP1 ADNP COX7B CPT2 CCDC103 ND1 DNAAF3 LRRC56 LRRC6 CCDC40 SLC25A1 SLC12A3 CFTR COQ7 SCO2 EDA SCO2 DMPK FOXF1 EFEMP2 PLCB4 UBE3B NKX2-1 OFD1 TRNK COL13A1 ITGA3 ETFDH COL2A1 DNAI2 SOX9 DNAJC21 SCO1 SYT2 USP9X DPM2 FGFR2 SSR4 USP9X COX10 CDC6 NDUFB11 CCDC114 FGFR2 DYNC2LI1 TRPV6 CDC45 DNAJB13 RPGR ATP6 CREBBP CLCNKB SIK1 CTRC DPM2 MMUT BMPER SPINK1 ERF MCIDAS HYDIN Protein Mutations 1
A118G SNP 1
rs7103572
Primary Outcomes
Description: Progression to ARDS is defined as the need for mechanical ventilation
Measure: Progression to ARDS Time: 28 daysSecondary Outcomes
Description: Blood PO2 as measured by pulse oximetry
Measure: Blood oxygenation Time: 28 daysDescription: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath = very mild shortness of breath = mild shortness of breath = moderate shortness of breath or breathing difficulty = somewhat severe shortness of breath = strong or hard breathing 7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity
Measure: RDP Dsypnea Scale Time: 28 daysDescription: Distance walked in six minutes
Measure: Distance walked in six minutes Time: 28 days